Published in Diabetes on April 01, 2004
Strategies to promote donor cell survival: combining preconditioning approach with stem cell transplantation. J Mol Cell Cardiol (2008) 2.16
K(ATP) channel therapeutics at the bedside. J Mol Cell Cardiol (2005) 1.27
The pancreas in human type 1 diabetes. Semin Immunopathol (2010) 1.11
Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data. Pediatr Diabetes (2008) 0.91
Some cannabinoid receptor ligands and their distomers are direct-acting openers of SUR1 K(ATP) channels. Am J Physiol Endocrinol Metab (2011) 0.81
The expression of the beta cell-derived autoimmune ligand for the killer receptor nkp46 is attenuated in type 2 diabetes. PLoS One (2013) 0.79
Beta-cell selective K(ATP)-channel activation protects beta-cells and human islets from human islet amyloid polypeptide induced toxicity. Regul Pept (2010) 0.76
Type-specific human papillomavirus detection in cervical smears in Romania. APMIS (2010) 0.75
The diabetes-prone BB rat carries a frameshift mutation in Ian4, a positional candidate of Iddm1. Diabetes (2002) 2.06
The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab (2002) 1.83
A novel high-affinity peptide antagonist to the insulin receptor. Biochem Biophys Res Commun (2008) 1.75
Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care (2002) 1.73
Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc Natl Acad Sci U S A (2007) 1.71
Long-term AICAR administration and exercise prevents diabetes in ZDF rats. Diabetes (2005) 1.71
Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes (2007) 1.64
Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes (2002) 1.46
An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin Cancer Res (2007) 1.38
Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res (2009) 1.32
The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes (2003) 1.30
GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol (2003) 1.23
IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother (2008) 1.22
Ian4 is required for mitochondrial integrity and T cell survival. Proc Natl Acad Sci U S A (2003) 1.19
Measurements of insulin responses as predictive markers of pancreatic beta-cell mass in normal and beta-cell-reduced lean and obese Göttingen minipigs in vivo. Am J Physiol Endocrinol Metab (2005) 1.07
In vivo control of diabetogenic T-cells by regulatory CD4+CD25+ T-cells expressing Foxp3. Diabetes (2005) 1.05
Mild streptozotocin diabetes in the Göttingen minipig. A novel model of moderate insulin deficiency and diabetes. Am J Physiol Endocrinol Metab (2002) 1.04
Interleukin-21 activates human natural killer cells and modulates their surface receptor expression. Immunology (2007) 1.03
Reconstitution of Scid mice with CD4+CD25- T cells leads to rapid colitis: an improved model for pharmacologic testing. Int Immunopharmacol (2006) 0.99
Both Gimap5 and the diabetogenic BBDP allele of Gimap5 induce apoptosis in T cells. Int Immunol (2007) 0.98
Immune activation in advanced cancer patients treated with recombinant IL-21: multianalyte profiling of serum proteins. Cancer Immunol Immunother (2008) 0.98
Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1. Diabetes (2002) 0.93
Inhibition of NKG2D receptor function by antibody therapy attenuates transfer-induced colitis in SCID mice. Eur J Immunol (2007) 0.93
Acute hyperglycemia alters the ability of the normal beta-cell to sense and respond to glucose. Am J Physiol Endocrinol Metab (2002) 0.91
Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity. J Med Chem (2002) 0.91
Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesus. Regul Pept (2009) 0.90
NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs. Eur J Pharmacol (2002) 0.89
Immunomodulatory dendritic cells require autologous serum to circumvent nonspecific immunosuppressive activity in vivo. Blood (2005) 0.89
Improved insulin sensitivity and islet function after PPARdelta activation in diabetic db/db mice. Eur J Pharmacol (2009) 0.88
Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats. Am J Physiol Endocrinol Metab (2002) 0.87
Phenylpiperidine selective serotonin reuptake inhibitors interfere with multidrug efflux pump activity in Staphylococcus aureus. Int J Antimicrob Agents (2003) 0.84
NN414, a SUR1/Kir6.2-selective potassium channel opener, reduces blood glucose and improves glucose tolerance in the VDF Zucker rat. Diabetes (2003) 0.83
Kir6.2-dependent high-affinity repaglinide binding to beta-cell K(ATP) channels. Br J Pharmacol (2005) 0.82
Establishment and characterization of a sustained delayed-type hypersensitivity model with arthritic manifestations in C57BL/6J mice. Arthritis Res Ther (2012) 0.82
Pharmacological Evaluation of the SCID T Cell Transfer Model of Colitis: As a Model of Crohn's Disease. Int J Inflam (2012) 0.82
Valine pyrrolidide preserves intact glucose-dependent insulinotropic peptide and improves abnormal glucose tolerance in minipigs with reduced beta-cell mass. Exp Diabesity Res (2003) 0.81
CD40 is required for development of islet inflammation in the RIP-CD154 transgenic mouse model of type 1 diabetes. Ann N Y Acad Sci (2007) 0.81
New autoimmune genes and the pathogenesis of type 1 diabetes. Curr Diab Rep (2004) 0.81
Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model. J Pharm Pharmacol (2012) 0.81
Comparative mapping of rat Iddm4 to segments on HSA7 and MMU6. Mamm Genome (2004) 0.81
Virtual screening for novel openers of pancreatic K(ATP) channels. J Med Chem (2007) 0.80
Possible role of an ischemic preconditioning-like response mechanism in K(ATP) channel opener-mediated protection against streptozotocin-induced suppression of rat pancreatic islet function. Biochem Pharmacol (2008) 0.80
The antiapoptotic gene Ian4l1 in the rat: genomic organization and promoter characterization. Gene (2004) 0.80
PolyI:C induction of diabetes is controlled by Iddm4 in rats with a full regulatory T cell pool. Ann N Y Acad Sci (2007) 0.79
Local activation of dendritic cells leads to insulitis and development of insulin-dependent diabetes in transgenic mice expressing CD154 on the pancreatic beta-cells. Diabetes (2004) 0.79
Arylcyanoguanidines as activators of Kir6.2/SUR1K ATP channels and inhibitors of insulin release. J Med Chem (2004) 0.78
Reactivity of naive CD4+CD25- T cells against gut microflora in healthy mice. Int Immunol (2006) 0.78
Nateglinide, but not repaglinide, stimulates growth hormone release in rat pituitary cells by inhibition of K channels and stimulation of cyclic AMP-dependent exocytosis. Eur J Endocrinol (2002) 0.78
Attenuation of hyperinsulinemia by NN414, a SUR1/Kir6.2 selective K-adenosine triphosphate channel opener, improves glucose tolerance and lipid profile in obese Zucker rats. Metabolism (2004) 0.77
Detection of gene expression signatures related to underlying disease and treatment in rheumatoid arthritis patients. Mod Rheumatol (2012) 0.77
K(ATP) channels and pancreatic islet blood flow in anesthetized rats: increased blood flow induced by potassium channel openers. Diabetes (2003) 0.76
Sensory nerve inactivation by resiniferatoxin improves insulin sensitivity in male obese Zucker rats. Am J Physiol Endocrinol Metab (2005) 0.76
Beta-cell selective K(ATP)-channel activation protects beta-cells and human islets from human islet amyloid polypeptide induced toxicity. Regul Pept (2010) 0.76
Flow sorting from organ material by intracellular markers. Cytometry A (2007) 0.76
Confirmation of a disease model of pemphigus vulgaris: characterization and correlation between disease parameters in 90 mice. Exp Dermatol (2010) 0.75
Explorative study of pharmacokinetics and pharmacodynamics after change in basal insulin infusion rate. J Diabetes Sci Technol (2011) 0.75
Synthesis and pharmacological evaluation of 4H-1,4-benzothiazine-2-carbonitrile 1,1-dioxide and N-(2-cyanomethylsulfonylphenyl)acylamide derivatives as potential activators of ATP sensitive potassium channels. Bioorg Med Chem (2005) 0.75
Toward tissue-selective pancreatic B-cells KATP channel openers belonging to 3-alkylamino-7-halo-4H-1,2,4-benzothiadiazine 1,1-dioxides. J Med Chem (2003) 0.75
A co-transfer system in young prediabetic BB rats: reactivated autoreactive T cells can be partly controlled. J Autoimmun (2003) 0.75
Synthesis and biological activity of 3,3-diamino-sulfonylacrylonitriles as novel inhibitors of glucose induced insulin secretion from beta cells. Bioorg Med Chem (2003) 0.75